INTRODUCTION
The incidence of fungal diseases is on the rise, in part as the result of increases in immunocompromised populations due to AIDS, cancer chemotherapy regimens, and immunosuppression for organ transplantation. The three predominant fungal pathogens in humans are Cryptococcus neoformans, Candida albicans, and Aspergillus fumigatus. C. neoformans is a basidiomycetous yeast that infects over one million immunocompromised individuals annually with mortality rates estimated at 70% in Latin America and subSaharan Africa (Park et al., 2009 ). The closely related species Cryptococcus gattii was associated with outbreaks of cryptococcosis in healthy individuals on Vancouver Island (Kidd et al., 2004) and other regions of the Pacific Northwest of North America, with mortality rates in excess of 30% (Byrnes et al., 2010) . Cryptococcus is therefore a substantial emerging threat to public health within and beyond the immunocompromised population.
Current regimens to treat cryptococcosis infection entail at least 1 year of therapy with flucytosine and intravenous infusions of amphotericin B, an almost impossible task in resource-limited health care settings (WHO, 2011) . Flucytosine is a DNA synthesis inhibitor used only as a combination agent due to the rapid emergence of resistance. Amphotericin B depletes essential membrane sterols by forming large extramembranous aggregates that extract the essential lipid ergosterol from the plasma membrane (Anderson et al., 2014) . Both of these frontline antifungal drugs are highly toxic to humans and difficult to administer. The azole antifungals also target ergosterol biosynthesis and represent an additional therapeutic option for treating C. neoformans infections (Ostrosky-Zeichner et al., 2010) . However, as fluconazole is only fungistatic, resistance can emerge rapidly. The only new class of antifungals to reach the clinical setting in decades, the echinocandins, target fungal cell wall biosynthesis but are completely ineffective at combatting Cryptococcus infections (Ostrosky-Zeichner et al., 2010) .
Natural products and their semisynthetic derivatives are the dominant source of small molecules with antimicrobial activity. Approximately 80% of all available clinically used antibiotics are derived from natural products (Roemer et al., 2011) . This success rests on the intrinsic properties of natural products, including enormous chemical diversity, favorable cell permeability characteristics, and exquisite target specificity crafted by evolution (Roemer et al., 2011) . Natural product-based drug discovery nevertheless presents challenges that include the tendency to rediscover previously characterized compounds, difficulties in resupplying source organisms that synthesize natural products, and challenges in deciphering compounds that account for extract-based activities.
To address the challenge of source organisms for natural product screening, we have compiled a collection of more than 10,000 actinomycete isolates, termed the Wright Actinomycete Collection (WAC). This rich source of natural products has been used to identify novel antibiotic adjuvants (Cox et al., 2014) , stimulators of macrophage activity (Perry et al., 2015) , and inhibitors of resistance determinants in Gram-negative bacteria (King et al., 2014) . We report the application of this collection to discover novel antifungal molecules. We used a co-culturing strategy to examine the effects of 150 actinomycete strains on the growth of the fungal pathogens C. albicans and C. neoformans. One actinomycete, WAC 2288, inhibited growth of C. neoformans with minimal effects on C. albicans, suggesting the production of a speciesspecific growth-inhibitory compound. Purification and structure elucidation identified the active compound, which we termed ibomycin, as a large type I polyketide macrolactone. Ibomycin altered cell membrane function and selectively permeated the cell wall of C. neoformans. These results establish ibomycin as the first member of a new class of antifungal agents.
RESULTS
A Co-culture Screen Identifies an Antifungal Activity Specific to C. neoformans We developed a simple co-culture method to test for diffusible activities produced by actinomycetes that altered the growth of C. albicans and C. neoformans. Bacteria were cultured for several days on solid medium to allow for the production and secretion of bioactive molecules. C. albicans or C. neoformans were then streaked alongside the actinomycetes patch and incubated for an additional several days. This solid-phase assay uncovered various effects on fungal growth and development ( Figure S1 ). We focused our attention on unique phenotypes, such as actinomycetes that preferentially inhibited the growth of one or the other fungal species in order to avoid producers of the relatively common and non-specific toxic polyenes. A single strain, WAC 2288, specifically inhibited the growth of C. neoformans with minimal effects on C. albicans ( Figure 1A) . In order to verify this antifungal activity, a methanolic extract was prepared. Disc-diffusion assays with increasing concentrations of extract resulted in dose-dependent growth inhibition of C. neoformans with no discernable growth-inhibitory effect on C. albicans ( Figure 1B ). Thus, WAC 2288 produces a soluble molecule(s) with selective anticryptococcal activity.
Purification of the Anticryptococcal Molecule WAC 2288 was originally isolated from a Nigerian soil sample and is related to Streptomyces clavuligerus, as inferred from 98% identity of the 16S rRNA sequence between these species (data not shown). Metabolites from WAC 2288 were recovered after growth in liquid Bennett's medium using HP-20 resin and separated by column fractionation. Activity-guided purification was used to isolate an exceptionally large and complex glycosylated macrolactone, which we termed ibomycin. To elucidate the compound structure, the purified active compound was subjected to high-resolution electrospray ionization mass spectrometry (HR-ESI-MS), as well as 1D and 2D nuclear magnetic resonance (NMR) (Figure 2 , Figure S2 and Table S1 ). Based on the HR-ESI-MS of m/z 1932.0407 [M + H] + coupled with inspection of NMR spectra we established the molecular formula to be C 92 H 158 N 2 O 40. The 1D-NMR spectra indicated the presence of seven sugar residues and a macrolide aglycone (Figure 2A ; see the Supplemental Experimental Procedures for a detailed description of NMR assignments). Based on analysis of 1 H-1 H COSY, HSQC-TOCSY, and HMBC NMR spectra, the sugar moieties corresponded to single subunits of vancosamine, glucose, and N-acetyl glucosamine along with two subunits each of rhamnose and rhodinose ( Figure 2B ). The structure of the macrolide aglycone was established through the analysis of 1 H-1 H COSY, HSQC, HSQC-TOCSY, and HMBC NMR spectra ( Figure S2 and Table S1 ). Two proton-spin systems were identified corresponding to H-2 to H-14 and H-16 to H-41 ( Figure 2C ), the assignment of which was reinforced through HMBC ( Figure S2H ). HMBC correlations enabled the connection of the two spin systems through a 34-membered macrolide ring ( Figure 2D ). In addition, these experiments confirmed the presence of an intramolecular ketal between C-19 and C-15 ( Figure 2D ). The geometries of the double bonds at C-2, C-4, C-28, and C-30 were assigned to be the E isomer, consistent with their large coupling constants ( Figure 2 and Table S1 ). The structure was completed by ordering of the sugar residues through their HMBC correlations between anomeric protons H-1A, H-1B, H-1C, H-1D, H-1E, H-1F, and H-1G, and oxymethine carbons C-13, C-2A, C-3A, C-21, C-39, C-4E, and C-4F, respectively ( Figure 2E ). The relative configurations of C-7, C-9, C-23, C-25, C-27, Figure 1 . Actinomycete-Fungal Pathogen Co-culturing Yields Anticryptococcal Phenotype from WAC 2288 (A) WAC strains were subcultured onto Bennett's agar horizontally and grown at 30 C for 3 days, after which C. neoformans and C. albicans were inoculated in close proximity. Plates were grown for 5 days at 30 C and the plates were imaged. (B) WAC 2288 was grown on Bennett's agar for 7 days. Methanol extracts were dried and resuspended in increasing volumes of methanol, and 15 mL was spotted on sterile discs that were overlayed on top of a lawn of C. neoformans or C. albicans. Plates were visualized after 3 days. Related to Figure S1 and Table S6 . C-35, C-36, and C-37 were further confirmed by 13 C NMR chemical shift (Helaly et al., 2012; Kobayashi et al., 2000) .
In Silico Identification of Biosynthetic Clusters Responsible for Ibomycin Production
A draft genome sequence of WAC 2288 was assembled using a combination of sequencing data from 454 pyrosequencing and mate-paired end Illumina sequencing. This assembly yielded an 8,680,593 bp genome in 237 contigs (N50 138,212 bp). Analysis of the genome sequence with the natural product prediction software antiSMASH (Medema et al., 2011) identified a single candidate cluster containing the predicted enzymes for the synthesis and assembly of a large type 1 polyketide along with genes for backbone accessorization, regulation of biosynthesis, and polyketide export/resistance ( Figure 3A and Table  S2 ) (GenBank: KJ159185). Each open reading frame was identified and annotated, yielding a 140 kbp span of DNA.
The genome sequence analysis predicted that the 41-carbon polyketide scaffold of ibomycin would be synthesized by 86 catalytic domains on 20 polyketide synthase (PKS) modules spread Figure S2 and Table S1. across seven multidomain PKS genes ( Figure 3B ). antiSMASH predicted that all enzymes in the ibomycin cluster should be functional and the order of the modules matched well with the production of a linear polyketide. One notable discrepancy between the chemical structure and the predicted domain arrangement was an order swap of modules 12 and 13 and a swap of modules 14 and 15 ( Figure 3B ). Although this module swapping is not a common feature of polyketide biosynthesis, examples of module stuttering (Gaitatzis et al., 2002; He and Hertweck, 2003) , skipping (Beck et al., 2002; Wenzel et al., 2005) , and other variations continue to be uncovered as more natural product assembly lines are discovered. We identified the docking domains in the translated sequences of all the PKS genes through antiSMASH and/or by generating alignments with previously characterized docking domain sequences (Table S3 ) (Medema et al., 2011; Thattai et al., 2007) . Sequence analysis of the 20 acyltransferase (AT) domains revealed 11 malonyl-coenzyme A (CoA) and 9 methyl malonyl-CoA as the presumptive substrates for the polyketide modules ( Figure S3 ). However, structural data suggested that only 7 methyl malonyl-CoA substrates were used in the biosynthesis of ibomycin. Analysis of the AT domains unveiled selected residues that deviated from standard sequences used to predict substrate specificity ( Figure S3 ) (Silakowski et al., 2001; Yadav et al., 2003) . Discrepancies in substrates used in the synthesis of polyketides compared with computational predictions of substrate specificity have been reported previously, including an example in the well-characterized myxalamid biosynthetic gene cluster (Chen et al., 2012; Silakowski et al., 2001; Takaishi et al., 2013) . Stereochemistry of the malonyl-CoA and methylmalonyl-CoA substrates at the a and b positions was verified from the sequence of the 18 ketoreductase domains (Figures 3  and S3 ). The remainder of the proposed 140 kbp ibomycin cluster included several genes with predicted regulation, sugar biosynthesis, efflux, and tailoring enzyme functions of a hydroxyl group to C-16, resulting in an altered spatial orientation of the C-15 carbonyl toward the C-19 hydroxyl group. This modification locks the molecule in a conformation that locates the C-1 carbonyl group in proximity to the hydroxyl moiety on C-37 and thereby allows formation of the hemiketal ring ( Figure 3B ). Several genes within this central cluster were predicted to be required for the biosynthesis of L-rhodinose, and the incorporation of N-acetylglucosamine is likely mediated by ibo11, a b-N-acetylhexosaminidase. Finally, two ATP-binding cassette transporters with homology to the Drr class of efflux proteins were present in the cluster and likely needed for export of the molecule from the cell.
The predicted ibomycin biosynthetic cluster does not include candidate genes responsible for the synthesis of vancosamine or rhamnose. We identified genes for vancosamine biosynthesis, annotated as ivaA-E, on a separate contig ( Figure S4 ) (GenBank: KJ159186). This arrangement is intriguing given that glycopeptide antibiotics containing vancosamine typically have genes required for their biosynthesis present within the main glycopeptide biosynthetic cluster (Donadio et al., 2005) . The arrangement of the iva genes is unconventional in that ivaA (a C2-dehydratase involved in the early stages of vancosamine biosynthesis) is located $74 kbp downstream of the other genes, embedded within a separate non-ribosomal peptide synthase-PKS hybrid cluster predicted by antiSMASH ( Figure S4 ). The rhamnose biosynthesis genes, annotated as irmA-D, are $38 kbp downstream of a cluster predicted to synthesize a terpene ( Figure S4 ) (GenBank: KJ159187). Based on this sequence-based annotation, we inferred a biosynthetic scheme for the sugars contained in the structure of ibomycin ( Figure S4 ). Unlike many biosynthetic pathways, these results suggest that three distinct biosynthetic clusters distributed across the genome are responsible for the synthesis of ibomycin.
Purified Ibomycin Inhibits Growth of Diverse Fungal Species
We assessed the activity of purified ibomycin against C. neoformans, C. albicans, and the model yeast Saccharomyces cerevisiae. Consistent with our initial observation in the coculture screen, C. neoformans was susceptible to ibomycin at a minimal inhibitory concentration (MIC) of 12.5 mg/mL, whereas C. albicans was only inhibited at 200 mg/mL ( Figure 4A ). S. cerevisiae showed an intermediate phenotype with an MIC of 25 mg/mL ( Figure 4A ). Time kill assays demonstrated that ibomycin is fungicidal against all three fungi ( Figure 4B ). In preliminary tests, ibomycin also displayed toxic effects in an in vitro hemolysis assay and in a metazoan model of fungal pathogenesis ( Figure S5 ).
We hypothesized that the differential sensitivity of ibomycin against C. neoformans compared with C. albicans or S. cerevisiae might be due to the ability of the drug to permeate the fungal cell wall to reach its intracellular target. This hypothesis predicted potential synergism between ibomycin and cell wall antagonists. Checkerboard dose-response assays with ibomycin and the cell wall disruptor caspofungin against C. albicans and S. cerevisiae uncovered potent synergism in both species ( Figure 4C) . No synergy was observed between caspofungin and ibomycin against C. neoformans (data not shown), likely because the echinocandins are ineffective against this species. Notably, potentiation of ibomycin was observed in C. neoformans and C. albicans upon the addition of the distinct cell wall perturbing agent calcofluor white ( Figure S6A) , and a C. neoformans mutant with defective capsule production (cap59D) reduced the MIC of ibomycin 2-fold ( Figure S6B ). Collectively, these drug susceptibility assays support the model that differences in cell wall composition limits entry of ibomycin into the cell.
Ibomycin Localizes to Membranous Compartments
To localize the possible site of action of ibomycin, we chemically linked the fluorescent dye BODIPY to the vancosamine sugar on ibomycin ( Figure S6C ). The ibomycin-BODIPY conjugate had comparable activity to ibomycin itself in dose-response assays ( Figure S6D ). We observed staining of the plasma membrane and intracellular membranes in C. neoformans upon treatment with ibomycin-BODIPY alone, whereas no fluorescence signal above background was observed in C. albicans or S. cerevisiae ( Figure 4D ). Incubation of C. albicans or S. cerevisiae with a subinhibitory dose of caspofungin resulted in a similar pattern of ibomycin-BODIPY localization to cellular membranes ( Figure 4D ). This result is consistent with the hypothesis that the differential species sensitivity to ibomycin arises from the ability of the compound to permeate the fungal cell wall.
Mechanism of Action of Ibomycin
We used chemical-genetic profiling in S. cerevisiae to investigate the mechanism of action of ibomycin. We profiled compound action in haploinsufficiency profiling screens, in which deletion strains heterozygous for essential genes were tested for sensitivity to ibomycin. Genes that encode the compound target are expected to be hypersensitive, as indicated by decreased competitive growth within the deletion strain pool (Giaever et al., 2004) . We also profiled compound action in homozygous deletion profiling screens, in which deletion strains for nonessential genes were tested for drug sensitivity to identify genes that buffer reduced activity of the targeted pathways (Giaever Figure 3 . Genome Sequencing Unveils the Ibomycin Biosynthetic Cluster (A) A 140 kbp cluster predicted to synthesize a type I PKS was found in the genome of WAC 2288 using antiSMASH. The cluster is composed of 40 genes, seven of which are responsible for production of the PKS scaffold. The remaining genes are involved in regulation, efflux, sugar biosynthesis, and decoration of the scaffold as indicated. (B) Modular biosynthesis of ibomycin according to the catalytic domains encoded by the PKS genes. Annotated ibo genes are displayed above via blue arrows and individual modules are shown with the intermediates attached to their respective acyl carrier protein (ACP) domains. The order of the domains as predicted by antiSMASH has been altered for consistency with the chemical structure of ibomcyin. Modules 12 and 13 are switched, as are modules 14 and 15. Ibo6 is proposed to add a hydroxyl group on C16 to induce formation of the hemiketal group and subsequent macrocyclization. Following scaffold production, the ibomycin aglycone is decorated with seven sugars. KS, ketosynthase; KR, ketoreductase; DH, dehydratase. Related to Figures S3, S4 , and Table S2 , S3. et al., 2004) . We carried out these screens at a concentration of 8 mg/mL, which conferred a growth rate defect of $20% over 22 hr in these experiments. Several deletion strains were significantly more sensitive to ibomycin ( Figure S6E and Table S4 ), as confirmed by growth curve analysis with individual deletion strains ( Figure S6F ). Our chemogenomic profile identified genes that were highly connected in regards to their physical interactions, supporting their biological relevance in response to ibomycin ( Figure 5A ). Gene ontology categories significantly enriched for processes in strains that were hypersensitive to ibomycin included: Golgi to vacuole transport, vacuolar transport, phospholipid transport, endosome, and actin cytoskeleton organization ( Figure 5A and Table S5 ). The proteins encoded by these various genes formed a highly connected interaction network ( Figure 5A ). Components of the endosomal sorting complexes required for transport (ESCRT) complexes including members of ESCRT-0 (VPS27), ESCRT-I (STP22, SRN2), ESCRT-II (VPS25, VPS36), ESCRT-III (SNF7, VPS20, VPS24), and VPS4, Figure 4 . Ibomycin Displays Fungicidal Antifungal Activity against Diverse Fungal Species (A) Minimum inhibitory concentration (MIC) assays were performed in yeast peptone dextrose (YPD) medium with 2-fold serial dilutions of ibomycin against diverse fungal species. Growth was measured by an optical density at 600 nm (OD 600 ) and data were quantitatively displayed with color using Treeview (see color bar). (B) Ibomycin exerts its antifungal activity in a fungicidal manner. Cells were cultured in synthetic complete (SC) with concentrations of ibomycin below or above the MIC. Growth and viability was measured by serial dilution and plating. Means for duplicate cultures ± SD are plotted . CFU, colonyforming units. (C) Checkerboard assays were performed in SC medium with 2-fold serial dilutions of ibomycin with 2-fold serial dilutions of caspofungin. Growth was measured by OD 600 and data were quantitatively displayed as described in (A). (D) Log-phase cultures of C. neoformans, S. cerevisiae, or C. albicans were treated with 25 mg/mL ibomycin-BODIPY for 1 hr without and with 25 ng/mL caspofungin. Cells were washed to remove excess dye. Micrographs were taken using a Nikon Eclipse TE200 microscope. Related to Figures S5 and S6. an ATPase that drives the activity of the ESCRT-III complex, were essential for viability in the presence of a subthreshold dose of ibomycin ( Figure 5A and Table  S4 ). The ESCRT machinery plays a vital role in cellular transport, as well as multivesicular body (MVB) and autophagic vacuole formation (Hurley and Hanson, 2010) , suggesting that ibomycin impeded cellular trafficking and/or altered vacuole and MVB formation. To investigate this possibility, we used the dye FM 4-64 to visualize specific intracellular organelles in S. cerevisiae upon treatment with ibomycin. FM 4-64 intercalates into the plasma membrane and is subsequently internalized by endocytosis such that it labels vacuoles and other compartments in the endocytic pathway (Vida and Emr, 1995) . Cells grown to exponential phase and stained with FM 4-64 showed uptake of the dye and staining of intracellular organelles (Figure 5B) . In contrast, cells treated with a sublethal concentration of ibomycin for 3 hr displayed poor staining with little internalization of dye and staining of intracellular compartments ( Figure 5B ). These chemical-genomic and cell biological data suggest that ibomycin disrupts endocytic trafficking.
Ibomycin Alters Membrane Fluidity and Function Independent of Ergosterol Binding
As ibomycin appeared to alter membrane structure and/or function, we assessed whether ibomycin exerted its effects through a direct interaction with ergosterol. In yeast, exogenous ergosterol is excluded from aerobically growing cells such that incubating an ergosterol-binding drug with ergosterol alleviates drug-induced toxicity (Raychaudhuri and Prinz, 2006; Zavrel et al., 2013) . As a positive control, incubation of the polyene amphotericin B (a known ergosterol binding compound) with ergosterol abrogated the toxic effects of the polyene in a dose-dependent manner in both C. albicans and S. cerevisiae ( Figure 6A ). In contrast, we observed no discernable effects upon incubation of ergosterol with ibomycin in either species (Figure 6A ), suggesting that ibomycin does not physically bind to ergosterol.
Environmental perturbations such as temperature fluctuations often disrupt membrane structure (Leach and Cowen, 2014) . Similarly, inhibition of ergosterol biosynthesis by the Figure 5 . Ibomycin Affects Cellular Transport and Membrane Function (A) Functional annotation of genes significantly sensitive to ibomycin in chemical-genomic assay (Z score < À2). Network and gene ontology (GO) enrichment were generated with GeneMania. Edges indicate physical interactions between gene products; edge weights reflect confidence in support for interactions. Node color corresponds to a set of functional gene classes picked manually from enriched GO categories (black nodes are not part of this set of classes). Colored bubbles highlight protein complexes that are enriched. (B) S. cerevisiae was treated with ½ MIC ibomycin for 3 hr prior to staining with membrane dye FM 4-64. Micrographs were taken using a Nikon Eclipse TE200 microscope. Related to Figure S6 , Tables S4, and S6. azoles results in the accumulation of toxic sterols within the membrane, thereby altering membrane organization and fluidity (Abe et al., 2009) . We assessed whether ibomycin altered membrane fluidity in a similar manner to elevated temperature and fluconazole. We performed MIC assays with ibomycin against C. albicans and C. neoformans at a variety of temperatures. The combination of elevated temperature with ibomycin against C. albicans caused a decrease in ibomycin MIC from 200 mg/mL at 24 C to 25 mg/mL at 42 C ( Figure 6B ). Although high temperatures reduced growth of C. neoformans in the absence of any compound, a modest decrease in growth temperature partly suppressed ibomyin sensitivity, consistent with an effect of ibomycin on membrane function. Similarly, ibomycin abolished the residual growth of a laboratory strain of C. albicans in the presence of the Erg11 inhibitor fluconazole, but had minimal effect on the growth of C. neoformans ( Figure 6C) . These data suggest that ibomycin compromises cell membrane integrity and fluidity in a manner that is independent from ergosterol binding.
DISCUSSION
The importance of antifungal drugs to the practice of modern medicine has never been greater due to the rise in invasive lifethreatening fungal infections. Yet the tempo of drug development is not keeping pace with clinical need. With rapid advances in genomic technologies coupled with a growing understanding of the mechanistic details of natural product biosynthesis, researchers are poised to overcome the innovation gap. Our discovery of ibomycin demonstrates that actinomycetes remain a Cell Chemical Biology 23, 1383-1394, November 17, 2016 1389 rich and largely untapped source of novel chemical matter. New insight into biosynthetic mechanisms suggests that the genetic potential of microbes to produce a diverse spectrum of compounds is vastly underestimated (Marmann et al., 2014) . Many microbial biosynthesis genes are silent under standard laboratory conditions and consequently only a fraction of total biosynthetic diversity has been explored. Co-culture of different species represents a new strategy to activate otherwise silent biosynthetic clusters (Angell et al., 2006; Marmann et al., 2014) . In our screen, growing multiple actinomycetes and fungal species alongside one another uncovered multiple phenotypes, including increased hyphal growth of C. albicans, alterations in pigment production, and species-specific antifungal activity. Thus, systematic screens under co-culture conditions may reveal a vast new diversity of natural products.
Our approach to screen for selective growth inhibition of a pathogenic fungal species circumvented the inefficient rediscovery of known toxic polyenes, and instead uncovered a new chemical scaffold after screening only 150 actinomycete species. Efforts to redeploy previously studied compounds, referred to as dark chemical matter (Wassermann et al., 2015) , as well as studies to identify synergistic chemical combinations (Robbins et al., 2015; Spitzer et al., 2011; Wildenhain et al., 2015) , have also yielded species-specific agents. Collectively, these results highlight that species-selective agents allow access to a much more diverse and accessible chemical space than pan-species antifungals. In principle, this strategy would be highly effective when combined with rapid early diagnostic tests for fungal infection in the patient.
Bioactive large macrolactone molecules that are structurally related to ibomycin have been reported recently (Kawahara et al., 2012) . Examples include novonestmycin A and B that act against phytopathogenic fungi (Wan et al., 2015) , gargantulide A that abrogates growth of methicillin-resistant Staphylococcus aureus (Rho et al., 2015) , and brasilinolide A that shows activity against Aspergillus niger (Tanaka et al., 1997) . Many of these molecules exhibit toxicity against mammalian cells as was also observed with ibomycin. However, the large macrolide liposidolide A is active against phytopathogenic fungi and C. albicans, but has limited toxicity in a mouse model of infection (Kihara et al., 1995) , suggesting that non-toxic derivatives of large macrocyclic lactones might be accessed. The transposition of liposidolide A modifications to the chemical structure of ibomycin, particularly to the sugar moieties, may mitigate toxicity issues associated with ibomycin.
Nature's ability to produce an incredible array of diverse and complex molecules with specific biological targets reflects the fact they are products of evolution selected over millennia. A vast majority of characterized natural product biosynthetic clusters possess all of their genes in a single genomic cluster, likely due to the requirement of precise and coordinated gene expression. Thus, we found it intriguing that genes required for both Figure 6 . Ibomycin Interacts with Cellular Membranes and Alters Membrane Fluidity and Function (A) Exogenous ergosterol competition assay. Addition of exogenous ergosterol in the media reverses amphotericin growth inhibition but has no effect on growth in the presence of ibomycin. Assays were performed in YPD medium with 2-fold serial dilutions of amphotericin B or ibomycin and 2-fold dilutions of ergosterol. Growth was measured by OD 600 and data were quantitatively displayed as described in Figure 4. (B) MIC assays were performed in SC medium with 2-fold serial dilutions of ibomycin at different temperatures. Growth was measured and analyzed as in (A). (C) Checkerboard assays were performed in SC medium with 2-fold serial dilutions of ibomycin with 2-fold serial dilutions of fluconazole. Growth was measured by OD 600 and data was quantitatively displayed as described in Figure 4 . vancosamine and rhamnose biosynthesis were not present with the genes required for the synthesis of the ibomycin aglycone backbone. Other notable cases where this has been reported include the synthesis of spinosyn (Madduri et al., 2001) and elloramycin (Ramos et al., 2008) , where rhamnose biosynthesis gene clusters were identified in other chromosomal locations. This suggests that at times there may be an evolutionary advantage to harbor genes required for chemical modifications at alternate sites in the genome, particularly if they can be shared by the cell for other cellular functions or chemical structures. From a synthetic biology perspective, this idea holds great promise to achieve increased chemical diversity in a single species.
SIGNIFICANCE
The steady rise of fungal infections over the past several decades, often associated with disease or therapies that compromise the immune system, is causing a serious burden on global health. Natural products are an invaluable source of therapeutic agents, but novel screening methods need to be employed to overcome the rediscovery of known molecules. This work describes a co-culturing strategy that identified a novel macrolactone, ibomycin. Several actinomycete and fungal species were cultured alongside one another, and the isolate WAC 2288 was selected for follow-up analysis as it strongly inhibited growth of C. neoformans with no discernible effects on C. albicans, suggesting a unique chemical scaffold was responsible for this selective growth-inhibitory phenotype.
Purification and structure elucidation identified the active compound as a large type I polyketide. To our knowledge, this is a novel chemical structure that has not been described or characterized in the literature. We uncovered three distinct biosynthetic clusters responsible for the synthesis of ibomycin. We speculate that this enables the cell to utilize the rhamnose and vancosamine biosynthesis genes for the creation of multiple chemical entities, expanding the cell's chemical potential and perhaps providing an evolutionary advantage. Chemical-genomic and cell biological assays implicated cellular membranes as the target of ibomycin. The preferential activity that ibomycin displayed toward C. neoformans was due to differences in the ability of the molecule to permeate through the fungal cell wall as treatment of C. albicans or S. cerevisiae with the cell wall antagonist caspofungin rendered these species exquisitely sensitive to ibomycin. Hence, actinomycete strains remain an invaluable source of novel chemical matter that can be used to identify and characterize novel antimicrobials.
EXPERIMENTAL PROCEDURES

Strains and Culture Conditions
Strains used in this study are listed in Table S6 and culture conditions are described in the Supplemental Experimental Procedures. Primers used in this study are listed in Table S6 .
Actinomycete-Fungal Pathogen Co-culturing Screen One hundred and fifty actinomycete strains were chosen based on unique phenotypes or interesting isolation environments and were streaked horizontally on the plate in a 4 3 2 pattern. Fungal pathogens C. neoformans H99 and C. albicans ATCC 90028 were streaked vertically on the agar after 2-10 days to accommodate the diverse range of actinomycete growth rates. Plates were incubated at 30 C for 2-7 days and monitored for the ability of a specific actinomycete strain to antagonize the growth of only one of the pathogens.
Purification of Ibomycin
For large-scale purification of ibomycin, a single colony of WAC 2288 was grown in 3 mL of Tryptic Soy Broth for 3 days at 30 C with aeration. Culture was diluted 1:100 into 50 mL of fresh Bennett's medium and grown for 3 days at 30 C with aeration. Culture was diluted 1:100 into 500 mL of fresh Bennett's medium and grown for 7 days at 30 C with aeration until the culture was a dark green color. The cell culture was filtered and the filtrate was incubated with 2% (w/v) Diaion HP-20 resin (Sigma-Aldrich) overnight. The resin was loaded on a 1 L column and molecules were eluted by gravity with 50% methanol (500 mL), and 100% methanol (1 L). Fractions were assessed for bioactivity using C. neoformans sensitivity as a guide throughout. Activity was observed in fractions eluted with 100% methanol. Bioactive fractions were concentrated using rotary evaporation for $1 hr at 36 C and 90 rpm. Active fractions were further purified by passage of Diaion HP-20 resin overnight. Molecules were eluted with 100% methanol. Purity of fractions was assessed by reverse-phase high-performance liquid chromatography (HPLC) coupled with MS detection (LC/MS).
Analytical LC-MS/NMR Analysis LC-ESI-MS data were obtained with an Agilent 1100 Series LC System (Agilent Technologies) and a QTRAP LC/MS/MS System (Applied Biosystems). Molecular weight calculated for Ibomycin C 92 H 158 O 40 N 2 [M + H] + was 1931.0391 Da, while that found was 1932.0469 Da. The reverse-phase HPLC was performed using a XSelect CSH analytical C18 column (Waters) (5 mm, 4.6 3 100 mm) with an Agilent 1100 LC binary pump at a flow rate of 1 mL/min under the following conditions: isocratic 32% solvent B (0.05% formic acid in acetonitrile) and 68% solvent A (0.05% formic acid in water) for 1 min, followed by a linear gradient to 38% B over 17 min, followed by a linear gradient to 100% B from 18 to 22 min.
Compound structure was confirmed by 1D and 2D NMR experiments on a Bruker Avance III 700 MHz (Billerica) equipped with a cryoprobe in deuterated methanol solvent. The NMR data from 1 H NMR, DEPTq, COSY, TOCSY, HSQC, HMBC, and semi-selective HMBC experiments were used to assign all 1 H and 13 C chemical shifts and elucidate the structure. Chemical shifts, which were referenced to the residual solvent signals of MeOH-d4, were 3.30 and 4.80 ppm for 1 H and 49.0 ppm for 13 C. HR-MS data were obtained using an Orbitrap XL Hybrid mass spectrometer (Thermo Fisher) equipped with an electrospray interface operated in positive ion mode using the following experimental parameters: sheath gas flow rate, 15 arb; auxiliary gas flow rate, 8 arb; capillary voltage, 30 V; capillary temperature, 200 C; spray voltage, 3.9 kV.
Next Generation Sequencing and Biosynthetic Cluster Identification
For genomic DNA extraction, a seed culture of WAC 2288 was inoculated into liquid Bennett's broth and allowed to incubate at 30 C for 4 days. Cells were lysed and DNA was extracted as described previously (Pospiech and Neumann, 1995) . gDNA was sheared into 1.5 kb fragments using an S220 Focused-ultrasonicator (Covaris) and libraries were prepared following the XL+ Rapid Library Preparation Method Manual (Roche 454 Life Sciences). Emulsuion PCR was performed and DNA-enriched beads were loaded onto a PicoTiterPlate (Roche 454 Life Sciences) according to specified parameters. Shotgun sequencing was performed on a Roche 454 Life Sciences GS FLX+ Genome Sequencer at the Farncombe Metagenomics Facility, McMaster University. gDNA was also submitted for mate-paired end Illumina sequencing on a MiSeq platform at the Donnelly Sequencing Centre, University of Toronto, following standard protocols. Genome assembly was conducted with 699,833 reads sequenced on the 454 platform (average read length of 550 bp, total 0.8 Gbp) and 1,782,036 pairs of Illumina reads (150 bp, total 0.534 Gbp) using MIRA v3.4.0 software using the ''genome,'' ''denovo'' and ''accurate'' quick switches (Chevreux et al., 1999) . This assembly was later refined using 4,491,355 Illumina mate-pair reads generated from a 3 kbp insert library scaffolded using SSPACE (Boetzer et al., 2011) . Detailed protocols for sequencing analysis can be found in the Supplemental Experimental Procedures. Biosynthetic cluster analysis was performed by antiSMASH (Medema et al., 2011) . For WAC 2288 characterization, genomic DNA was prepared by standard methods (Pospiech and Neumann, 1995) . For 16S rRNA analysis, PCR was performed using primers F27 and R1492. Amplicons were sequenced at the MOBIX Central Facility (McMaster University, Hamilton, Canada) . The 16S rRNA gene sequence from WAC 2288 was subjected to BLASTN analysis against the NCBI database, and the highest scoring match was from Streptomyces clavuligerus ATCC 27064 strain NRRL 3585 with a sequence identity of 98%.
Drug-Susceptibility Assays
All compounds were purchased from Sigma-Aldrich with the exception for caspofungin (Cancidas), which was purchased from Merck. DMSO (Sigma-Aldrich) was the solvent for all compounds. MIC tests and checkerboard assays were performed in U-bottom, 96-well microtiter plates (Thermo Fisher Scientific) using a modified broth microdilution protocol as described previously (Singh et al., 2009) . In brief, assays were set up in a total volume of 0.2 mL/well with 2-fold dilutions of drug in synthetic complete (SC) or yeast peptone dextrose (YPD) medium as indicated. Plates were incubated in the dark for 48-72 hr, and absorbance was determined at 600 nm using a spectrophotometer (Molecular Devices). Each strain was tested in duplicate on at least two occasions. Data were quantitatively displayed with color using the program Java TreeView 1.1.6 (http://jtreeview.sourceforge.net). For growth curve analysis, overnight cultures were diluted to an optical density at 600 nm (OD 600 ) of 0.0625 in YPD, with or without the compound as indicated, and grown at 30 C with continuous shaking using Sunrise (Tecan). OD 595 was measured every 15 min over 24-48 hr. Data were plotted and analyzed using GraphPad Prism.
Viability Assays
Duplicate cultures for each condition were grown in liquid SC at 30 C with constant agitation. The starting inoculum was normalized to 1 3 10 6 cells/mL; samples were removed at the indicated times and colony-forming unit counts assessed by serial dilution and plating.
Chemical-Genomic Assays S. cerevisiae deletion collections (MATa haploid and heterozygous essential deletion strains) were obtained from Research Genetics. Compounds were screened at a concentration that inhibited growth of the pool by $20% relative to a solvent control. Deletion pools were grown for 24 hr at 30 C, at which point gDNA was extracted using phenol-chloroform extraction methods. The purified gDNA was used to amplify the barcoded tags upstream of the KANMX cassette using various primer combinations (Table S6 ). PCR products were gel excised (Invitrogen) and DNA samples were pooled and sequenced at the Farncombe Metagenomics Facility at McMaster University. Details of sequencing analysis are described in the Supplemental Experimental Procedures.
Fluorescence Microscopy
An ibomycin-BODIPY conjugate was synthesized as described in the Supplemental Experimental Procedures. To determine where ibomycin was localizing, log-phase cultures of C. neoformans, S. cerevisiae, and C. albicans were treated with 25 mg/mL of Ibomycin-BODIPY is the absence and presence of 25 ng/mL caspofungin. Cultures were incubated with agitation in the dark at 30 C for 1 hr. At this point, cell pellets were washed twice with PBS before being resuspended in PBS. Cells were visualized using an inverted Nikon Eclipse TE200 microscope at 1,0003 magnification. Micrographs were acquired using NIS-Elements Advanced Research software.
For vacuole membrane staining with FM 4-64FX (catalog no. F34653, Invitrogen), cells were grown overnight in YPD medium 30 C with agitation. The next morning, cells were diluted to an OD 600 of 0.2 without and with ½ MIC ibomycin and allowed to grow for 3 hr. Cells were incubated with 8 mM FM 4-64 for 30 min at 30 C. Cells were washed and continuously pulsed with FM 4-64 for an additional 60 min. Cells were resuspended in SC media and visualized as described above.
Exogenous Ergosterol Competition Assay
Exogenous ergosterol competition assays were performed as described previously with slight modifications (Yibmantasiri et al., 2012) . In brief, ergosterol dissolved in ethanol, or ethanol solvent control, was preincubated in 50 mL of YPD media containing a gradient of ibomycin or amphotericin B in U-bottom, 96-well microtiter plates (Thermo Fisher Scientific) for 3 hr. Subsequently, 50 mL of S. cerevisiae or C. albicans at a density of 1 3 10 6 cells/mL were added and the plates incubated at 30 C. The OD 590 was measured using a spectrophotometer after 24 hr incubation.
ACCESSION NUMBERS
The accession numbers for the ibomycin biosynthesis genes, vancosamine biosynthesis genes, and rhamnose biosynthesis genes reported in this paper are GenBank: KJ159185, KJ159186, and KJ159187, respectively. 
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